RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT06139107
This study is recruiting at 4 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to assess the benefits of concurrent use of these treatments in a specific participant population, focusing on their safety and tolerability. The hypothesis is that the combination therapy will be well-tolerated, providing valuable insights into its effectiveness for future clinical applications.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 60 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Mridula George, MD
- Last updated on ClinicalTrials.gov
- November 14, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 4
- RWJBarnabas Health Clara Maas Medical Center · Belleville, NJ
- Cooperman Barnabas Medical Center · Livingston, NJ
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
- RWJBarnabas Health - Robert Wood Johnson University Hospital Somerset · Somerville, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.